Cancer Targeted Technology
Cancer Targeted Technology (CTT) is a biotechnology company dedicated to developing innovative small molecule drugs for cancer diagnosis and therapy. Their mission is to design and patent targeted agents that accurately detect, stratify, treat early and advanced disease, and monitor treatment efficacy to improve patient survival and quality of life. CTT's technology focuses on targeting the Prostate-Specific Membrane Antigen (PSMA), a biomarker expressed on prostate tumors and other solid tumors, using their proprietary irreversibly binding small molecules. They develop diagnostic imaging agents, such as CTT1057, and therapeutic agents, including CTT1403 and CTT2274, for prostate cancer and potentially other cancers. Their pipeline includes several agents in various stages of development, with collaborations and licensing agreements with companies like Novartis and Bayer. CTT aims to provide precise, safe, and effective tools for cancer detection, treatment, and monitoring.
Industries
Nr. of Employees
small (1-50)
Cancer Targeted Technology
14241 NE Woodinville-Duvall Road, #143, Woodinville, WA 98072
Patents
Products
CTT1057
An 18F-labeled PET imaging agent targeting PSMA for detection and localization of prostate cancer and metastatic lesions; completed Phase I clinical study and progressed to further clinical evaluation by a licensee.
CTT1403
A PSMA-targeted radiotherapeutic labeled with lutetium-177, incorporating an albumin-binding motif to extend circulation and increase tumor uptake; completed preclinical studies and a Phase I clinical trial.
CTT2274
A small-molecule drug conjugate (SMDC) that uses the PSMA-targeting scaffold to deliver monomethyl auristatin E (MMAE) via a pH-sensitive/prodrug linker, designed to release cytotoxin intracellularly and reduce off-target toxicity; IND-enabling studies supported by SBIR funding.
CTT1057
An 18F-labeled PET imaging agent targeting PSMA for detection and localization of prostate cancer and metastatic lesions; completed Phase I clinical study and progressed to further clinical evaluation by a licensee.
CTT1403
A PSMA-targeted radiotherapeutic labeled with lutetium-177, incorporating an albumin-binding motif to extend circulation and increase tumor uptake; completed preclinical studies and a Phase I clinical trial.
CTT2274
A small-molecule drug conjugate (SMDC) that uses the PSMA-targeting scaffold to deliver monomethyl auristatin E (MMAE) via a pH-sensitive/prodrug linker, designed to release cytotoxin intracellularly and reduce off-target toxicity; IND-enabling studies supported by SBIR funding.
Services
Out-licensing and collaboration of clinical-stage imaging and therapeutic candidates to third parties for further development and commercialization.
Out-licensing and collaboration of clinical-stage imaging and therapeutic candidates to third parties for further development and commercialization.
Expertise Areas
- Radiopharmaceutical development
- PSMA-targeted diagnostics and therapeutics
- Small-molecule drug conjugates (SMDC) and prodrug design
- Preclinical efficacy, biodistribution and dosimetry
Key Technologies
- Phosphoramidate-based PSMA-targeting scaffold
- Fluorine-18 PET radiotracers
- Lutetium-177 radiotherapeutics
- Small-molecule drug conjugates (SMDC)
News & Updates
CTT to Present Data on Prostate Cancer Therapy Candidates at Upcoming Conferences
The company will present clinical and preclinical data on CTT1057 and CTT1403 at scientific meetings in June and April.
Cancer Targeted Technology Announces Advances with its PSMA-targeted Agents at Conferences
The company will showcase progress on its diagnostic and therapeutic agents for prostate cancer at upcoming scientific meetings.
Development of CTT1403 from Concept to First-in-Human Studies
Carolyn Anderson presented on the development of CTT1403 at the Anaheim, CA conference in June 2019.
Lutetium Based PSMA-Targeted Therapeutics: A 'Game-Changer' for Prostate Cancer
Beatrice Langton-Webster presented on CTT1403 in Seattle, WA, in March 2019.
Preclinical radiation dose optimization of CTT1403
Xiaoxi Ling presented on preclinical studies of CTT1403 in Philadelphia, PA, in June 2018.
Panelist at NCI SBIR Panel Session
Beatrice Langton-Webster discussed translating cancer technologies at a Chicago, IL, session in April 2018.
CTT to Present Data on Prostate Cancer Therapy Candidates at Upcoming Conferences
The company will present clinical and preclinical data on CTT1057 and CTT1403 at scientific meetings in June and April.
Cancer Targeted Technology Announces Advances with its PSMA-targeted Agents at Conferences
The company will showcase progress on its diagnostic and therapeutic agents for prostate cancer at upcoming scientific meetings.
Development of CTT1403 from Concept to First-in-Human Studies
Carolyn Anderson presented on the development of CTT1403 at the Anaheim, CA conference in June 2019.
Lutetium Based PSMA-Targeted Therapeutics: A 'Game-Changer' for Prostate Cancer
Beatrice Langton-Webster presented on CTT1403 in Seattle, WA, in March 2019.
Preclinical radiation dose optimization of CTT1403
Xiaoxi Ling presented on preclinical studies of CTT1403 in Philadelphia, PA, in June 2018.
Panelist at NCI SBIR Panel Session
Beatrice Langton-Webster discussed translating cancer technologies at a Chicago, IL, session in April 2018.